2024-04-15 08:15:00 ET
Summary
- Amgen has a history of outperforming peers and the market due to its effective capital allocation in the pharmaceutical industry.
- AMGN is executing well with sales and volume growth, and has a robust development pipeline.
- Biosimilars growth is accelerating and AMGN currently offers value at the current price along with a respectable and well-covered dividend yield.
Anybody who's invested in the pharmaceutical space knows that industry giants like Pfizer ( PFE ) and Gilead Sciences ( GILD ) are subject to boom and bust cycles as it relates to patent cliffs and new drug development. That's why capital allocation is so important to sustaining shareholder returns, and those who can do it well tend to outperform peers and even the market itself....
Read the full article on Seeking Alpha
For further details see:
Amgen: I Prefer To Chase Value And Dividends